Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study

for the Israeli myeloma study group

doi:10.1111/bjh.18479

Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study

for the Israeli myeloma study group

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Belantamab mafodotin, an immuno-conjugate targeting B-cell maturation antigen, showed single-agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real-world data and long-term follow-up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One-hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2–11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow-up time was 11.9 [95% confidence interval (CI) 10.0–13.8] months. Overall response rate was 45.5%. Median progression-free survival was 4.7 (95% CI 3.5–5.9) months in the entire cohort and 8.8 (95% CI 6.6–10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5–19.6) months, and not reached for responders. To conclude, in a real-world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile.

Original language	American English
Pages (from-to)	45-53
Number of pages	9
Journal	British Journal of Haematology
Volume	200
Issue number	1
DOIs	https://doi.org/10.1111/bjh.18479
State	Published - Jan 2023

Bibliographical note

Funding Information:
The Israeli Belantamab Mafodotin compassionate care programme was supported by GSK. The authors wish to thank Claire Wardel D.Phil and the GSK Israel Belantamab Mafodotin expanded compassionate programme for their collaboration. The authors wish to thank Mr Nathan Melamed from the haematology institute, Tel-Aviv Sourasky Medical Center, for his technical support preparing the figures.

Funding Information:
The Israeli Belantamab Mafodotin compassionate care programme was supported by GSK. The authors wish to thank Claire Wardel D.Phil and the GSK Israel Belantamab Mafodotin expanded compassionate programme for their collaboration. The authors wish to thank Mr Nathan Melamed from the haematology institute, Tel‐Aviv Sourasky Medical Center, for his technical support preparing the figures.

Publisher Copyright:
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Keywords

immunotherapy
multiple myeloma
myeloma therapy

Access to Document

10.1111/bjh.18479

Cite this

@article{280fb4e60e564cab87f5068a71df6cc5,

title = "Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study",

abstract = "Belantamab mafodotin, an immuno-conjugate targeting B-cell maturation antigen, showed single-agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real-world data and long-term follow-up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One-hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2–11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow-up time was 11.9 [95% confidence interval (CI) 10.0–13.8] months. Overall response rate was 45.5%. Median progression-free survival was 4.7 (95% CI 3.5–5.9) months in the entire cohort and 8.8 (95% CI 6.6–10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5–19.6) months, and not reached for responders. To conclude, in a real-world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile.",

keywords = "immunotherapy, multiple myeloma, myeloma therapy",

author = "{for the Israeli myeloma study group} and Tamir Shragai and Hila Magen and Noa Lavi and Moshe Gatt and Svetlana Trestman and Miri Zektser and Chezi Ganzel and Osnat Jarchowsky and Tamar Berger and Tamar Tadmor and Merav Leiba and Katrin Hertzog-Tzarfaty and Netanel Horowitz and Michael Shapira and David Varssano and Yoav Berger and Shahar Frenkel and Mark Krauthammer and Irit Avivi and Efrat Luttwak and Cohen, {Yael C.}",

note = "Funding Information: The Israeli Belantamab Mafodotin compassionate care programme was supported by GSK. The authors wish to thank Claire Wardel D.Phil and the GSK Israel Belantamab Mafodotin expanded compassionate programme for their collaboration. The authors wish to thank Mr Nathan Melamed from the haematology institute, Tel-Aviv Sourasky Medical Center, for his technical support preparing the figures. Funding Information: The Israeli Belantamab Mafodotin compassionate care programme was supported by GSK. The authors wish to thank Claire Wardel D.Phil and the GSK Israel Belantamab Mafodotin expanded compassionate programme for their collaboration. The authors wish to thank Mr Nathan Melamed from the haematology institute, Tel‐Aviv Sourasky Medical Center, for his technical support preparing the figures. Publisher Copyright: {\textcopyright} 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2023",

month = jan,

doi = "10.1111/bjh.18479",

language = "American English",

volume = "200",

pages = "45--53",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "1",

}

TY - JOUR

T1 - Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma

T2 - A multicentre retrospective study

AU - for the Israeli myeloma study group

AU - Shragai, Tamir

AU - Magen, Hila

AU - Lavi, Noa

AU - Gatt, Moshe

AU - Trestman, Svetlana

AU - Zektser, Miri

AU - Ganzel, Chezi

AU - Jarchowsky, Osnat

AU - Berger, Tamar

AU - Tadmor, Tamar

AU - Leiba, Merav

AU - Hertzog-Tzarfaty, Katrin

AU - Horowitz, Netanel

AU - Shapira, Michael

AU - Varssano, David

AU - Berger, Yoav

AU - Frenkel, Shahar

AU - Krauthammer, Mark

AU - Avivi, Irit

AU - Luttwak, Efrat

AU - Cohen, Yael C.

N1 - Funding Information: The Israeli Belantamab Mafodotin compassionate care programme was supported by GSK. The authors wish to thank Claire Wardel D.Phil and the GSK Israel Belantamab Mafodotin expanded compassionate programme for their collaboration. The authors wish to thank Mr Nathan Melamed from the haematology institute, Tel-Aviv Sourasky Medical Center, for his technical support preparing the figures. Funding Information: The Israeli Belantamab Mafodotin compassionate care programme was supported by GSK. The authors wish to thank Claire Wardel D.Phil and the GSK Israel Belantamab Mafodotin expanded compassionate programme for their collaboration. The authors wish to thank Mr Nathan Melamed from the haematology institute, Tel‐Aviv Sourasky Medical Center, for his technical support preparing the figures. Publisher Copyright: © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

PY - 2023/1

Y1 - 2023/1

N2 - Belantamab mafodotin, an immuno-conjugate targeting B-cell maturation antigen, showed single-agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real-world data and long-term follow-up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One-hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2–11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow-up time was 11.9 [95% confidence interval (CI) 10.0–13.8] months. Overall response rate was 45.5%. Median progression-free survival was 4.7 (95% CI 3.5–5.9) months in the entire cohort and 8.8 (95% CI 6.6–10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5–19.6) months, and not reached for responders. To conclude, in a real-world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile.

AB - Belantamab mafodotin, an immuno-conjugate targeting B-cell maturation antigen, showed single-agent activity in phase 1 and 2 studies, and was recently approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Real-world data and long-term follow-up are scarce. We conducted a multisite retrospective study aimed to assess safety and efficacy of belantamab mafodotin monotherapy administered via the GSK expanded access compassionate care programme. One-hundred and six RRMM patients were treated with belantamab mafodotin between July 2019 and March 2021. The median age was 69.4 years. Patients were heavily pretreated with a median of six (range 2–11) prior therapy lines. Major adverse effects included ocular toxicity (keratopathy 68.4%, grade ≥3: 40.5%; blurred vision 36.8%, grade ≥3: 6.3%), thrombocytopenia (27.4%, grade ≥3: 17.9%) and infections (11.3%, grade ≥3: 7.5%). Median follow-up time was 11.9 [95% confidence interval (CI) 10.0–13.8] months. Overall response rate was 45.5%. Median progression-free survival was 4.7 (95% CI 3.5–5.9) months in the entire cohort and 8.8 (95% CI 6.6–10.9) months among responders. Median overall survival was 14.5 (95% CI 9.5–19.6) months, and not reached for responders. To conclude, in a real-world setting, belantamab mafodotin monotherapy showed efficacy comparable with the prospective clinical trials, with a tolerable toxicity profile.

KW - immunotherapy

KW - multiple myeloma

KW - myeloma therapy

UR - http://www.scopus.com/inward/record.url?scp=85139381494&partnerID=8YFLogxK

U2 - 10.1111/bjh.18479

DO - 10.1111/bjh.18479

M3 - Article

C2 - 36205375

AN - SCOPUS:85139381494

SN - 0007-1048

VL - 200

SP - 45

EP - 53

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this